42 results about "Joint synovium" patented technology

A method of determining the voltage and current required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage in the treatment of osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffold, growth factors, etc.) for treating cartilage defects in the human hip joint and a device for delivering such signals to a patient's hip. Anatomic, analytical, and planar circuit models are developed to determining the impedances, conductivities, and current flows in the human hip joint and its surrounding soft tissues and skin that are required to produce a 20 mV / cm electric field in the synovium and articular cartilage of the human hip. The voltage of the signal applied to the surface electrodes or to a coil(s) or solenoid is varied based on the size of the hip joint; larger hip joints require larger voltages to generate the effective electric field.

The invention discloses a strain of Bifidobacterium breve that can relieve rheumatoid arthritis and its application, belonging to the technical field of microorganisms. The invention screened out a strain of Bifidobacterium breve CCFM1078, and the Bifidobacterium breve CCFM1078 has the effect of relieving rheumatoid arthritis, which is embodied in: significantly promoting the secretion of anti-inflammatory factor IL-10 by RAW264.7 cells; Joint thickness, clinical score, and morbidity in rheumatoid arthritis rats; significantly reduced serum pro-inflammatory cytokines TNFα and IL-1β in rheumatoid arthritis rats; significantly modulated feces in rheumatoid arthritis rats The content of short-chain fatty acids; significantly reduce the proportion of Th17 cells in the mesenteric lymph nodes of rheumatoid arthritis rats; significantly reduce the secretion of the pro-inflammatory factor IL-6 by synovial cells.

The invneiton provides a cadinane sesquiterpene compound, and a preparation method and application thereof. The preparation method comprises the following steps: (1) preparation of fissistigma oldhamii extract: carrying out cold leaching or hot extracting on dried stem of the fissistigma oldhamii by using ethanol of which the volume concentration is 30 to 95 percent, thus obtaining an extracting solution; carrying out vacuum concentration, thus obtaining paste, i.e., the fissistigma oldhamii extract; (2) separation and purification: diluting the fissistigma oldhamii extract by using water to prepare a suspension solution, sequentially extracting by using petroleum ether and ethyl acetate, forming extractum by carrying out vacuum concentration on an ethyl acetate extracting solution, and carrying out column chromatography, thin layer chromatography, molecular sieve chromatographic separation and high-performance liquid-phase separation, thus obtaining the cadinane sesquiterpene compound. The invention also discloses the preparation method of the cadinane sesquiterpene compound and the application of the cadinane sesquiterpene compound in preparing medicine for resisting rheumatoid arthritis. According to the cadinane sesquiterpene compound disclosed by the invention, the activity of the cadinane sesquiterpene compound in inhibiting synovial cell proliferation of the rheumatoid arthritis is firstly discovered, and the cadinane sesquiterpene compound can be used for preparing the medicine for resisting the rheumatoid arthritis.

The present invention provides N 6 Use of -(2-hydroxyethyl)adenosine in the treatment of gout. Cordyceps Extract N 6 ‑(2‑hydroxyethyl)adenosine has a good analgesic effect by activating adenosine A1 receptors. By giving gout rats N 6 ‑(2‑hydroxyethyl), 932 genes were differentially expressed in the joint synovium, of which 57 were pain-related genes and 12 were analgesia-related genes. N 6 ‑(2‑Hydroxyethyl)adenosine significantly reduced joint swelling, levels of interleukin 1β (IL‑1β) and tumor necrosis factor alpha (TNF‑α) in serum and joint washing fluid, and decreased NLRP3 inflammasome , the level of caspase-1 (caspase-1), and promote autophagy and p62 degradation, play an anti-inflammatory and analgesic effect. Can be used to relieve pain and inflammation caused by gout.

A traditional Chinese medicine preparation is used as a new medicine for treating osteoarthritis. The clinical symptoms of osteoarthritis are: degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic degeneration, bone hyperplasia at the joint edge, synovial hyperplasia, Joint capsule contracture, ligament laxity or contracture, muscle atrophy and weakness, etc.; the traditional Chinese medicine preparation is made of the following raw materials in parts by weight: 700-1100 parts of red fish eye, 700-1100 parts of nine-layer wind, 450-800 parts of Ivy clover , 450-800 parts of Shanfeng, 160-320 parts of Liangmianzhen, 25-40 parts of Panax notoginseng stems and leaves, among which Shanfeng can also be replaced by an equal amount of Dafeng AI. The present invention uses the medicine originally used for treating rheumatoid arthritis, frozen shoulder and rheumatoid arthritis to treat osteoarthritis, and has remarkable curative effect in treating osteoarthritis, expands the indications of the original medicine, and provides a clinical A new drug for the prevention and treatment of osteoarthritis.